Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer

Muscle and Nerve

Volumn 52, Issue 2, 2015, Pages 307-308

  Loochtan, Aaron I ^a   Nickolich, Myles S ^a   Hobson Webb, Lisa D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IMMUNOGLOBULIN; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; PREDNISONE; MONOCLONAL ANTIBODY;

AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPLETE HEART BLOCK; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; EATON LAMBERT SYNDROME; HUMAN; LETTER; MALE; MONOTHERAPY; MYASTHENIA GRAVIS; NERVE STIMULATION; PACEMAKER IMPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; PTOSIS; REPETITIVE NERVE STIMULATION; SEPSIS; SMALL CELL LUNG CANCER; TREATMENT DURATION; CHEMICALLY INDUCED; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA;

AGED; ANTIBODIES, MONOCLONAL; HUMANS; LUNG NEOPLASMS; MALE; MYASTHENIA GRAVIS; SMALL CELL LUNG CARCINOMA;

EID: 84937520489     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24648     Document Type: Letter

References (12)

1. A phase 1/2, open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors (to be published).
2. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372;311-319.
3. Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh LF, et al. Safety, correlative markers and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015;21:712-720.
4. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for Metastatic Renal Cell Carcinoma: results of a randomized phase II trial. J Clin Oncol 2014 Dec 1. pii: JCO.2014.59.0703.
5. Ramalingam SS, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: metastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;90:1266-1267.
6. Tomasini P, Khobta N, Greillier L, Barlesi F. Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol 2012;4:43-50.
7. Mao HT, Wang XB, Zhang L, Gu HT. Studies on the genetic pathogenesis of myasthenia gravis caused by CTLA-4 gene polymorphism. Chinese J Med Genet 2004;21:574-578.
8. Johnson DB, Saranga-Perry V, Lavin PJM, Bryan Burnette W, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2014;32:1-3.
9. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014;16:589-593.
10. Peltier AC, Black BK, Raj SR, Donofrio P, Robertson D, Biaggioni I. Coexistent autoimmune autonomic ganglionopathy and myasthenia gravis associated with non-small-cell lung cancer. Muscle Nerve 2010;41:416-419.
11. Sakamaki Y, Yoon HE, Oda N. Non-small-cell lung cancer associated with non-thymomatous myasthenia gravis. Jpn J Thorac Cardiovasc Surg 2006;54:207-211.
12. Blanco P, Viallard JF, Pellegrin JL, Moreau JF. Cytotoxic T lymphocytes and autoimmunity. Curr Opin Rhumatol 2005;17:731-734.